MannKind Corporation
MNKD
Updated: 23/09/2026, 03:43:12
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
No summaries found.
- Share price
- $3.49
- Market cap
- $1.11B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Michael E. Castagna
- Employees
- 592
- IPO date
- 28/07/2004
- Beta
- 1.099
- Last dividend
- $0.00
- Day range
- $3.26 – $3.55
- 52-week range
- $2.23 – $6.51
- 1-day performance
- -0.29%
- 1-year performance
- 56.50%
- Current drawdown (1Y)
- -46.39%
- CIK
- 0000899460
- CUSIP
- 56400P706
- ISIN
- US56400P7069
- Created
- 07/12/2025, 05:17:21
- Last update
- 23/09/2026, 03:43:12
Track MannKind Corporation with an AI analyst
See which prediction-market events move MNKD, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
GlobeNewsWire • STOCK • 05/06/2026, 21:35:00
Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems
Globe News Wire • STOCK • 05/06/2026, 21:35:00
MannKind At An Inflection Point: Pediatric Expansion Drives The Story
Seeking Alpha • STOCK • 03/06/2026, 00:40:35
Wells Fargo Raises Price Target for MannKind (NASDAQ: MNKD) Following Pediatric FDA Approval
Market Data • Market Data • 01/06/2026, 05:05:50
MannKind Wins FDA Approval for Afrezza in Children, Opening Pediatric Diabetes Market
MarketBeat • STOCK • 31/05/2026, 01:07:54
MannKind Corporation (MNKD) Discusses FDA Approval of Afrezza for Pediatric Diabetes Patients Ages 6 and Older Transcript
Seeking Alpha • STOCK • 29/05/2026, 21:24:04
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval
GlobeNewsWire • STOCK • 29/05/2026, 16:00:00
US FDA approves MannKind's inhaled insulin for children
Reuters • STOCK • 29/05/2026, 14:44:05
MannKind to Present at Jefferies Global Healthcare Conference
GlobeNewsWire • STOCK • 27/05/2026, 18:00:00
MannKind Corporation (MNKD) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 07/05/2026, 15:01:25
MannKind: It's Complicated
Seeking Alpha • STOCK • 07/05/2026, 14:50:06
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics
Zacks Investment Research • STOCK • 06/05/2026, 22:31:09